摘要
目的对比瑞舒伐他汀逐日给药与间日给药对低密度脂蛋白胆固醇(LDL-C)水平已达标的冠状动脉疾病患者的血脂和超敏C反应蛋白(hs-CRP)的影响。方法将52例LDL-C水平已达标的冠状动脉疾病患者随机分为试验组与对照组,各26例。试验组患者逐日给予瑞舒伐他汀5 mg,对照组患者间日给予瑞舒伐他汀5 mg,经6周治疗后,分别考察LDL-C及hs-CRP水平的变化。结果纳入患者平均年龄(55.1±8.91)岁;治疗6周后,试验组的LDL-C水平明显低于对照组[(87±21)mg/d L比(106±25)mg/d L,P=0.008],LDL-C水平降低幅度显著低于对照组[(0.8±0.2)%比(34.2±6.7)%,P=0.001],而hs-CRP水平增减幅度组内治疗前后及组间比较无显著差异(P>0.05)。结论对于LDL-C及hs-CRP水平已达标的冠状动脉疾病患者,维持LDL-C水平达标,瑞舒伐他汀间日给药5 mg劣于逐日给药,但两者对于降低hs-CRP水平具有相似作用。
Objective To compare the effect of alternate-day and daily administration of rosuvastatin on levels of serum lipid and hs-CRP of patients with coronary artery disease（CAD） whose levels of LDL-C are up to standard.Methods Totally 52 patients with CAD whose levels of LDL-C were up to standard were randomly divided into the experimental group and the control group,26 cases in each group.The experimental group was given rosuvastatin 5 mg daily,while the control group was given rosuvastatin 5 mg every other day.After 6 weeks of treatment,the changes of LDL-C and hs-CRP were examined.Results The average age of the patients was（55.1 ± 8.91） years.After 6 weeks of treatment,the level of LDL-C in the experimental group was（87 ± 21） mg/d L,which was significantly lower than（106 ± 25） mg/d L of the control group（P = 0.008）.The level of LDL-C in experimental group was significantly decreased than that in the control group [（0.8 ± 0.2） % vs（34.2 ± 6.7） %,P = 0.001 ].The levels of hs-CRP in the two groups had no significant difference before and after treatment,and the levels of hs-CRP had no significant difference between the two groups after treatment（P 〉 0.05）.Conclusion For patients with CAD whose levels of LDL-C are up to standard,maintenance on al ternate-day rosuvastatin 5 mg was inferior to daily rosuvastatin in keeping LDL-C below the target level,however,they have similar effect on hs-CRP.
作者
袁浩宇
王鹏
俞瑜
Yuan Haoyu Wang Peng Yu Yu(416 Hospital of Nucleus Industry Ministry, Chengdu, Sichuan, China 610051)
出处
《中国药业》
CAS
2017年第15期38-40,共3页
China Pharmaceuticals
关键词
瑞舒伐他汀
间日给药
逐日给药
低密度脂蛋白胆固醇
超敏C反应蛋白
rosuvastatin
alternate-day administration of drug
daily administration of drug
low-density lipoprotein cholesterol
high-sen-sitivity C-reactive protein
